JP2024516748A5 - - Google Patents
Info
- Publication number
- JP2024516748A5 JP2024516748A5 JP2024508815A JP2024508815A JP2024516748A5 JP 2024516748 A5 JP2024516748 A5 JP 2024516748A5 JP 2024508815 A JP2024508815 A JP 2024508815A JP 2024508815 A JP2024508815 A JP 2024508815A JP 2024516748 A5 JP2024516748 A5 JP 2024516748A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2021901226A AU2021901226A0 (en) | 2021-04-26 | EGFRvIII BINDING PROTEINS II | |
| AU2021901227A AU2021901227A0 (en) | 2021-04-26 | EGFRvIII BINDING PROTEINS I | |
| AU2021901227 | 2021-04-26 | ||
| AU2021901226 | 2021-04-26 | ||
| PCT/AU2022/050379 WO2022226584A1 (en) | 2021-04-26 | 2022-04-26 | EGFRvIII BINDING PROTEINS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024516748A JP2024516748A (ja) | 2024-04-16 |
| JPWO2022226584A5 JPWO2022226584A5 (https=) | 2025-04-22 |
| JP2024516748A5 true JP2024516748A5 (https=) | 2025-04-22 |
Family
ID=83846542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024508815A Pending JP2024516748A (ja) | 2021-04-26 | 2022-04-26 | ＥＧＦＲｖＩＩＩ結合タンパク質 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240207407A1 (https=) |
| EP (1) | EP4330285A4 (https=) |
| JP (1) | JP2024516748A (https=) |
| AU (1) | AU2022267410A1 (https=) |
| WO (1) | WO2022226584A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240005794A (ko) * | 2021-05-18 | 2024-01-12 | 쑤저우 카노바 바이오파마슈티컬 컴퍼니 리미티드 | 항 pd-1 폴리펩티드 및 그의 용도 |
| AU2024360934A1 (en) * | 2023-10-13 | 2026-04-09 | The General Hospital Corporation | Treating glioblastoma using car-t cell therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2958943T3 (da) * | 2013-02-20 | 2019-12-09 | Univ Pennsylvania | Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor |
| TWI731535B (zh) * | 2014-03-21 | 2021-06-21 | 美商艾伯維有限公司 | 抗-egfr抗體及抗體藥物結合物 |
| MX2017001229A (es) * | 2014-07-29 | 2017-05-01 | Pfizer | Receptores de antigenos quimericos especificos de egfrviii para inmunoterapia de cancer. |
| WO2020172553A1 (en) * | 2019-02-22 | 2020-08-27 | Novartis Ag | Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors |
| KR20210148228A (ko) * | 2019-03-27 | 2021-12-07 | 내셔날 리서치 카운실 오브 캐나다 | 항-EGFRvIII 항체 및 그의 항원-결합 단편 |
-
2022
- 2022-04-26 EP EP22794091.3A patent/EP4330285A4/en active Pending
- 2022-04-26 WO PCT/AU2022/050379 patent/WO2022226584A1/en not_active Ceased
- 2022-04-26 JP JP2024508815A patent/JP2024516748A/ja active Pending
- 2022-04-26 AU AU2022267410A patent/AU2022267410A1/en not_active Abandoned
- 2022-04-26 US US18/288,475 patent/US20240207407A1/en active Pending